8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

___________________________________

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):  October 17, 2007

HUMAN PHEROMONE SCIENCES, INC.

(Exact name of Registrant as specified in its charter)

CALIFORNIA	0-23544	94-3107202
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)

84 W. SANTA CLARA STREET, SUITE 720, SAN JOSE, CALIFORNIA 95113

(Address of principal executive offices)       (Zip code)

Registrant’s telephone number, including area code:         (408) 938-3030                        

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(B))

¨

Pre-commencement communications pursuant to Rule 13e-4(c)) under the Exchange Act (17 CFR 240.13e-4c))

ITEM 8.01

Other Events

On October 17, 2007, Human Pheromone Sciences, Inc. (the Registrant, the “Company” or “HPS”) announced the filing of a Provisional Patent Application with the U.S. Patent and Trademark Office for the use of a compound found in nature which has significant positive impacts on both men and women.  The patent application is broad-based and covers the use of this compound in a host of potential consumer, personal care, household and environmental products.

ITEM 9.01.

Financial Statements and Exhibits.

(d)

Exhibits

99.2

Press Release dated October 17, 2007.

- 2 -

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HUMAN PHEROMONE SCIENCES INC.

Date:  October 17, 2007

By: /s/ William P. Horgan                 

       William P. Horgan, Chief Executive Officer

- 3 -

EXHIBIT INDEX

99.2 Press Release dated October 17, 2007.

- 4 -

EX-99

Exhibit 99.2

For Further Information:

Human Pheromone Sciences, Inc.

84 West Santa Clara Street, Suite 720

San Jose, CA  95113

(408) 938-3030

Contact:  

William P. Horgan

Chairman, CEO

For Immediate Release

Human Pheromone Sciences Names Additional Director

San Jose, California, October 17, 2007.  Human Pheromone Sciences, Inc. (OTC Bulletin Board: EROX) (“HPS” or “the Company”) announced today that it filed a Provisional Patent Application with the U.S. Patent and Trademark Office for the use of a novel compound found in nature which has significant positive impacts on both men and women.

“Our scientists have been working for more than eight years, from the initial discovery of this naturally-occurring compound that has its roots in the sea, reproducing it in the laboratory, conducting scientific trials with male and female volunteers and developing a manufacturing process for commercial quantities. Physiological and psychological testing has shown statistically significant increases in a host of positive emotions and feelings in both men and women, including increased feelings of wellness, warmth, sensuality and personal well-being.

“This is a very exciting discovery by our scientists, and the results of human testing exceeded our initial expectations. The patent application is broad-based and covers the use of this compound in a host of potential consumer, personal care, household and environmental products,” a Company spokesperson indicated.  The spokesperson also disclosed that it is actively working on other novel compounds that have shown positive results in preliminary research studies.

5

Human Pheromone Sciences, Inc. is a technology-based company, whose proof-of concept products included prestige-priced fragrances and toiletries and environmental products sold under the Natural Attraction®, REALM®, innerREALM® and EROX® trademarks.  These products contain mood-enhancing compounds, whose efficacy has been validated at leading universities around the world, and whose use is covered under United States and foreign patents. The Company has also entered into agreements with leading consumer products companies, such as Avon Products, Johnson & Johnson and Schwarzkopf & Henkel to incorporate the Company’s initial technology in their consumer products. The Company is also involved in research and product development efforts on new compounds that have been previously identified as stimulating the emotional centers of the human brain. Further information is available on line at www.erox.com.

The statements in this news release may contain forward-looking statements that involve risks and uncertainties that could cause results to differ from predicted results.  Further information on factors that could affect the Company’s results is detailed in the Company’s annual report to shareholders on Form 10-KSB for the year ended December 31, 2006, and Form 10-Q for the six months ended June 30, 2007 as filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements.

6